AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 294 min read$BMY

Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook

Bristol Myers Squibb (BMY) reported Q3 2026 revenue of $13.07B, up 7% YoY, and raised its 2026 sales outlook to $49.75B-$50.25B. Adjusted EPS was $1.35, beating estimates. Growth Portfolio revenue rose 12%, while adjusted gross margin fell to 68.4%. Shares rose over 2% post-announcement.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 2:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The key tradable change is the raised 2026 revenue forecast and the updated adjusted EPS range, alongside a noted decline in adjusted gross margin tied to product mix and a one-time contract termination charge.

02

Market read

Guidance raise after an earnings beat is a direct catalyst for near-term positioning in BMY and for pharma sentiment around growth portfolio execution.

03

What to watch

The guidance update includes a negative $0.60 per-share impact from acquired in-process R&D charges and licensing income, so investors may scrutinize underlying earnings power versus one-time or accounting effects.

Relevance 9/10Novelty 9/10Timing: post-market reaction day, shares rose more than 2% after the announcement

Background

Bristol Myers Squibb is updating its 2026 full-year outlook after reporting Q3 results that beat analysts on both EPS and revenue.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers Squibb reported Q3 EPS of $1.35 and revenue of $13.07B, then raised 2026 revenue guidance to $49.75B-$50.25B.

Expected impact

Likely upward pressure as the market prices in the higher 2026 revenue midpoint and the updated adjusted EPS range.

Evidence & confidence

The article is a first-report earnings and guidance update with explicit upside to revenue guidance and a Q3 beat on both EPS and revenue.

Market effects

Sector

Signals continued demand and execution in large-cap pharma, potentially supporting sentiment toward oncology and legacy brands.

Regional

Primarily US large-cap pharma sentiment; limited direct spillover beyond the sector.

Global

Moderate, as guidance updates can influence global pharma peers’ read-through on demand and margin trajectory.

Counterpoint

What could challenge this read

The adjusted gross margin fell to 68.4% from 72.9%, which could cap upside if investors focus on profitability deterioration despite revenue growth.

Key entities

  • company
    Bristol Myers Squibb

    Reported Q3 2026 results and raised 2026 revenue guidance; updated adjusted EPS guidance.

Read at source← All news

StoryBristol‑Myers Squibb posts Q3 beat, lifts 2026 revenue outlook and trims full‑year EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$LLYMed

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

finance.yahoo.com2 min
OCT 29
$NVSLow

4 Long-Term Survival Results From ESMO 2026 Patients Should Know

Novartis reported 6-year data from the NATALEE trial showing Kisqali (ribociclib) reduced death risk by 19% in early breast cancer. Merck's Keytruda (pembrolizumab) showed 7-year survival benefits in kidney cancer. Bristol-Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated lasting survival in colorectal cancer. Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combinations showed 3-year survival gains in stomach/esophageal cancer. All treatments were FDA-approved previously.

curetoday.com3 min
OCT 29
$BMYMedAI 8/10

BMS Flounders As Opdivo Lags, Earnings Guidance Cut

Bristol Myers Squibb (BMY) reported Q3 adjusted earnings of $1.35 per share, beating estimates of $1.10, with revenue of $13.07B, also exceeding expectations. The company cut its full-year earnings guidance due to weaker-than-expected sales of its cancer drug, Opdivo. BMY shares declined on the news.

investors.com2 min
OCT 29
$BMYHighAI 9/10

Why is Bristol-Myers Squibb stock gaining today?

Bristol-Myers Squibb (BMY) stock rose 1.5% in pre-market trading after reporting Q3 2026 adjusted EPS of $1.35, beating estimates of $1.09–$1.10, and revenue of $13.07 billion, exceeding forecasts of $12.72 billion. The company raised its full-year 2026 revenue guidance to $49.75–$50.25 billion. Growth Portfolio revenue increased 12% year-over-year to $7.7 billion. The stock traded lower than its 52-week high ahead of earnings.

investing.com4 min